TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02866136

Intervention type: DEVICE
Group type: OTHER
Intervention: Laser (local treatment)

Intervention type: DEVICE
Group type: OTHER
Intervention: cryoapplication (local treatment)

Intervention type: DEVICE
Group type: OTHER
Intervention: cryoapplication (local treatment)

Intervention type: DEVICE
Group type: OTHER
Intervention: cryoapplication (local treatment)

Intervention type: RADIATION
Group type: OTHER
Intervention: I125 radioactive plaques (local treatment)

Intervention type: RADIATION
Group type: OTHER
Intervention: I125 radioactive plaques (local treatment)
Study: NCT03452540

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1000mg DS102 (BID)
Description: Participants assigned to the open label pilot phase received 1000mg DS102 (BID)for 28 days.
Study: NCT02056743

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CYP cocktail
Description: Each group administered CYP cocktail (Caffeine 200mg + Losartan 50mg + Omeprazole 20mg + Dextromethorphan 30mg + Midazolam 7.5mg) under fasting conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CYP cocktail
Description: Each group administered CYP cocktail (Caffeine 200mg + Losartan 50mg + Omeprazole 20mg + Dextromethorphan 30mg + Midazolam 7.5mg) under fasting conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fexofenadine 30mg
Description: Each group administered Fexofenadine 30mg under fasting conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fexofenadine 30mg
Description: Each group administered Fexofenadine 30mg under fasting conditions.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Red ginseng
Description: During 4\~17th days, end of the period 1, the group of red ginseng administered red ginseng extract.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fermented-red ginseng
Description: During 4\~17th days, end of the period 1, the group of fermented-red ginseng administered fermented-red ginseng extract.
Study: NCT05081908

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiosurgery
Description: Multisession radiosurgery (hypofractionated radiotherapy) with Cyberknife
Study: NCT02913703

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ghrelin
Description: Boluses of Ghrelin will be given over a 1 minute period at 3 ug/kg. Ensure (2 cans) will also be given.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ghrelin
Description: Boluses of Ghrelin will be given over a 1 minute period at 3 ug/kg. Ensure (2 cans) will also be given.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ghrelin
Description: Boluses of Ghrelin will be given over a 1 minute period at 3 ug/kg. Ensure (2 cans) will also be given.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ghrelin
Description: Boluses of Ghrelin will be given over a 1 minute period at 3 ug/kg. Ensure (2 cans) will also be given.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saline
Description: Boluses of saline will be given over a 1 minute period. Ensure (2 cans) will also be given.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saline
Description: Boluses of saline will be given over a 1 minute period. Ensure (2 cans) will also be given.
Study: NCT02570178

Intervention type: OTHER
Group type: OTHER
Intervention: balance training
Description: Participants complete 2 sessions per week for 30 minutes each, over a period of three months and are distributed in groups of four individuals carrying out the exercises at once.The groups were led by monitors who had received standardized training. Each participant was barefoot on the balance board, carrying out the different exercises in the balance area of the Wii Fit™ game, according to the indications made on the screen.Eight out of the nine balance exercises were used from the Wii Fit™ game (balance bubble, soccer heading, ski jump, table tilt, ski slalom, penguin slide, snowboard slalom, tightrope walk);.The number of repetitions of each exercise varied depending on the skill of the participants but the total time dedicated to each exercise was the same for all group participants.
Study: NCT00976846

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dialyzer Baxter Xenium XPH 210
Description: High-Flux dialyzer
Study: NCT01380353

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac epolamine patch
Description: Patch (10cm X 14cm) is comprised of an adhesive material containing 1.3% diclofenac epolamine which is applied to a non-woven polyester felt backing and covered with a polypropylene film release liner \[B\].

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac epolamine patch
Description: Patch (10cm X 14cm) is comprised of an adhesive material containing 1.3% diclofenac epolamine which is applied to a non-woven polyester felt backing and covered with a polypropylene film release liner \[B\].
Study: NCT01045460

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Activated marrow infiltrating lymphocytes
Description: Administered on Days 3 and 4.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Activated marrow infiltrating lymphocytes
Description: Administered on Days 3 and 4.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic Myeloma Vaccine
Description: Allogeneic granulocyte macrophage colony-stimulating factor (GM-CSF)-based myeloma cellular vaccine. Administered on Days 21, 60, 180, and 300.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Administered at 2.5 g/m\^2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Administered at 2.5 g/m\^2.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Administered post cyclophosphamide daily until leukapheresis.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Administered post cyclophosphamide daily until leukapheresis.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Leukapheresis
Description: Performed approximately 12 days post cyclophosphamide. Exact date depends on peripheral blood CD34+ cell counts.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Leukapheresis
Description: Performed approximately 12 days post cyclophosphamide. Exact date depends on peripheral blood CD34+ cell counts.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: 100 mg/m\^2/day given on Days -2 and -1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: 100 mg/m\^2/day given on Days -2 and -1.
Study: NCT02866136

Intervention type: RADIATION
Group type: OTHER
Intervention: I125 radioactive plaques (local treatment)

Intervention type: DRUG
Group type: OTHER
Intervention: intravitreal Melphalan (local treatment)

Intervention type: DRUG
Group type: OTHER
Intervention: intravitreal Melphalan (local treatment)

Intervention type: DRUG
Group type: OTHER
Intervention: intravitreal Melphalan (local treatment)
Study: NCT02824081

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Blood sample
Description: Blood sample in order to study inflammatory biomarkers and genetics purpose
Study: NCT01045460

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous stem cell transplant
Description: Infused on Day 0.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous stem cell transplant
Description: Infused on Day 0.
Study: NCT04891614

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PRISM
Description: Subjects will complete 15 neurofeedback training sessions delivered twice per week, on non-consecutive days, over 8 consecutive weeks.
Study: NCT02319200

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: 1000 mg (2x500 mg) at morning and 1000 mg (2x500 mg) at afternoon (2000 mg per day)~Metformin daily during 36 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo tablet
Description: 4 tablets per day for 36 months
Study: NCT01333748

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: blood collection
Description: blood collection for research quantification of allelic expression in the gene BRCA1.

Intervention type: GENETIC
Group type: OTHER
Intervention: blood collection
Description: blood collection for research quantification of allelic expression in the gene BRCA1.
Study: NCT04177706

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine Hydrochloride
Description: Participants receiving the active study medication will receive 60 mg ketamine twice per week for four weeks under clinical supervision.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants receiving the placebo study medication will receive saline twice per week for four weeks under clinical supervision.
Study: NCT00472108

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Photodynamic Therapy (PDT)

Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Photodynamic Therapy (PDT)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metvix cream

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Cream
Study: NCT00574808

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Outreach Facilitation implementing elements of the Chronic Care Model
Description: An outreach facilitator helps the practice identify areas for improvement, set goals and targets, and agree on the processes needed to reach them in order to improve the care delivery within the practices. Each facilitator will be assigned up to 12 practice sites. The first year of program implementation will involve frequent (once every 3-4 weeks) visits to the practices. Afterwards, the intervention will move into a sustainability mode, during which the frequency of visits will decrease to one every 6-8 weeks during the second year, and one every 12-15 weeks during the third year and thereafter. After the first year of program implementation, each facilitator will be able to take on 12 new practices during the second year, while still being able to sustain contact with the previous 12 practices. Similarly, in the third year, another set of 12 practices will begin the intense phase of program implementation.
Study: NCT01101217

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zinc Supplement
Description: in 50 patients zinc sulfate 220 mg per day orally for 6 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo daily for 6 weeks
Study: NCT03828032

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mannitol injection
Description: Standard mannitol injection to decrease intracranial pressure of patients

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hypertonic saline injection
Description: Standard Hypertonic saline injection to decrease intracranial pressure of patients
Study: NCT00642356

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbidopa/levodopa/entacapone
Description: Carbidopa/levodopa/entacapone 25/100/200 mg tablets plus placebo immediate release carbidopa/levodopa capsules, administered orally for 8 weeks. Total daily dosage and frequency of dosing for each patient was determined by the investigator and stabilized upon entry into the study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Immediate release carbidopa/levodopa
Description: Immediate release carbidopa/levodopa 25/100 mg capsules plus placebo carbidopa/levodopa/entacapone tablets, administered orally for 8 weeks. The maximum daily dose is 800 mg. Total daily dosage and frequency of dosing for each patient was determined by the investigator.
Study: NCT00298324

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Myfortic
Description: 1440mg twice daily

Intervention type: DRUG
Group type: OTHER
Intervention: Prednisone and Cyclosporine
Description: Prednisone and Cyclosporine given according to protocol. The drugs are tapered according to patient response
Study: NCT01472640

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: liraglutide
Description: 1.8 mg sc QOD

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 1 U sc QOD
Study: NCT03488095

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: BCI for SLT and BQ Use in Adolescents: A CRT
Description: BCI for SLT and BQ Use in Adolescents: A CRT is aimed towards changing Adolescenst behaviors regarding their SLT and BQ use to as to reduce Oral cancer Burden within population because of this.
Study: NCT02144181

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ulthera System Treatment
Description: Focused ultrasound energy delivered below the surface of the skin

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ulthera System Treatment
Description: Focused ultrasound energy delivered below the surface of the skin

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ulthera System Treatment
Description: Focused ultrasound energy delivered below the surface of the skin

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ulthera System Treatment
Description: Focused ultrasound energy delivered below the surface of the skin
Study: NCT04458636

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prednisolone
Description: Oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone
Description: Oral
Study: NCT04386369

Intervention type: OTHER
Intervention: Airway pressure release ventilation
Description: Ventilator management strategy
Study: NCT00933699

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LACTIC ACID(ND)
Description: Treatment duration: 21 consecutive days
Study: NCT01697215

Intervention type: OTHER
Intervention: AirWave
Study: NCT00967564

Intervention type: OTHER
Intervention: epidemiologic study
Description: QoL assessment
Study: NCT03799146

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MyPlan 2.0
Description: MyPlan 2.0 consists of five sessions. During these five sessions the following behaviour change techniques are used to motivate users to be more physically active or to sit less: exploring risk perceptions and perceived benefits, exploring social support, providing feedback, action planning, coping planning and monitoring.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Waiting List
Description: Waiting List control group
Study: NCT03939546

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: B. infantis EVC001
Description: Bifidobacterium longum subspecies infantis strain EVC001, designated a Foods for Special Dietary Use (FSDU)
Study: NCT04612335

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rate control
Description: Rate control drugs are administered to obtain symptom relief and a heart rate of \<110 bpm, followed by a 4-week telemonitoring period.

Intervention type: OTHER
Group type: OTHER
Intervention: Pharmacological or electrical cardioversion
Description: Pharmacological or electrical cardioversion is performed to achieve restoration of sinus rhythm, either acutely or in a wait-and-see approach, all within 48 hours, and followed by a 4-week telemonitoring period.
Study: NCT02196896

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: deprexis®
Description: Online self-help program in addition to inpatient psychosomatic treatment for 90 days.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Information
Description: The patients receive online information about depression once a week for 90 days.
Study: NCT03553901

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupressure
Description: Acupressure was performed before the injection onto GB30 point
Study: NCT01168323

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online spaced education
Description: Spaced education is currently delivered via periodic emails that contain clinical case scenarios and multiple-choice questions. Upon submitting answers to each question online, clinicians receive immediate feedback and educational material. The questions are then repeated over spaced intervals of time to harness the pedagogical benefits of the spacing effect.
Study: NCT01559636

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: bivalent oral polio vaccine
Description: vaccine given during immunization campaigns

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: bivalent oral polio vaccine
Description: vaccine given during immunization campaigns
Study: NCT02482376

Intervention type: RADIATION
Group type: OTHER
Intervention: Stereotactic body radiotherapy ( SBRT)
Description: Single fraction of 21 Gy stereotactic radiotherapy (SBRT)delivered pre-operatively to subjects with early stage breast cancer
Study: NCT04232319

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Hygiene Training
Description: The intervention will last approximately 45 minutes, and will be provided once/week for 3 weeks. The intervention is delivered live using web-cameras (e.g., Microsoft Zoom).~Registered and licensed occupational therapists will deliver the intervention. Each week, the interventionist will guide the participant through a workbook to provide knowledge regarding sleep hygiene strategies and examples on how to apply these strategies to improve sleep quality.
Study: NCT02350517

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel+Nedaplatin+Endostar
Description: Patients will receive chemotherapy every 3 weeks: Paclitaxel 175mg/m2 IV over 3 hours on Day 4; Nedaplatin 80mg/m2 IV over 1 hours on Day 4; Endostar 3mg/day for 14 days continuous infusion from Day 1 to Day 14
Study: NCT03106571

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomaglumetad methionil
Description: Tablets twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomaglumetad methionil
Description: Tablets twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomaglumetad methionil
Description: Tablets twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1-4 tablets twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methamphetamine
Description: intravenous methamphetamine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methamphetamine
Description: intravenous methamphetamine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methamphetamine
Description: intravenous methamphetamine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methamphetamine
Description: intravenous methamphetamine
Study: NCT01074775

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Gut infection challenge with M bovis
Description: Oral delivery of 100mg viable M bovis (approximately 10,000,000 viable bacilli) in 5mL 1.5% sodium glutamate solution on three occasions on days 0, 28 and 49
Study: NCT02333461

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants were randomly assigned to receive one of four botanical interventions or placebo.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Apple
Description: Participants were randomly assigned to receive one of four botanical interventions or placebo.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Grape
Description: Participants were randomly assigned to receive one of four botanical interventions or placebo.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Raspberry
Description: Participants were randomly assigned to receive one of four botanical interventions or placebo.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Apricot/Nectarine
Description: Participants were randomly assigned to receive one of four botanical interventions or placebo.
Study: NCT04297865

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A dose as CJ-15314
Description: A dose as CJ-15314, 1 capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B dose as CJ-15314
Description: B dose as CJ-15314, 1 capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C dose as CJ-15314
Description: C dose as CJ-15314, 1 capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D dose as CJ-15314
Description: D dose as CJ-15314, 2 capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E dose as CJ-15314
Description: E dose as CJ-15314, 1 capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F dose as CJ-15314
Description: F dose as CJ-15314, 2 capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo, 1 capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo, 1 capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo, 1 capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo, 2 capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo, 1 capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo, 2 capsules
Study: NCT03803306

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Vedic Medical Astrology
Description: Individualised astrological based interventions were given including vedic counselling, diet, colors, gems, mantras and the worship deities as an adjuvent to ongoing conventional treatments

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Placebo vedic medical astrology (PMA)
Description: Conventional treatments were followed with counselling and diet suggestions. astrological interventions were not incorporated during the study phase.
Study: NCT04978883

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT02848131

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Group 2: Dasatinib
Description: Dasatinib - take one 100 mg tablet by mouth once daily for 3 consecutive days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Group 2: Quercetin
Description: Quercetin - take four 250 mg capsules daily (total 1000 mg daily) for 3 consecutive days.
Study: NCT03070951

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OBE2109
Description: OBE2109 100mg tablets for oral administration once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OBE2109
Description: OBE2109 100mg tablets for oral administration once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OBE2109
Description: OBE2109 100mg tablets for oral administration once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OBE2109
Description: OBE2109 100mg tablets for oral administration once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: OBE2109
Description: OBE2109 100mg tablets for oral administration once daily
Study: NCT03763032

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Counseling
Description: The patient navigator will provide educational materials, assessments, and counseling to the patients